摘要
目的探讨生长抑素联合复方丹参注射液治疗重症急性胰腺炎的临床疗效。方法选取2012年1月至2012年12月期间急性胰腺炎患者92例为研究对象,采用对照研究的方法,利用随机数表将其分为对照组和联合用药组,每组46例。两组接受综合疗法,其中对照组加用生长抑素,联合用药组则在对照组的基础上加用复方丹参注射液,分别观察两组的疗效、不良反应情况、血清C反应蛋白(CRP)和细胞间黏附分子-1(ICAM-1)指标,探讨联合用药的的临床应用价值。结果经治疗,联合组和对照组的患者病情均有不同程度的改善,联合用药组的有效率为93.48%,对照组的有效率为88.10%,联合用药组的有效率明显高于对照组,差异有统计学意义(P<0.05)。联合用药组出现8例不良反应,不良反应率17.39%;对照组出现7例不良反应,不良反应率15.22%;经卡方检验,两组的不良反应发生率差异无统计学意义(χ2=6.459,P>0.05)。治疗后两组各指标均有改善,与治疗前相比,差异有显著性(P<0.05)。且联合用药组CRP和ICAM-1在治疗后明显优于对照组,差异有统计学意义(P<0.05)。结论生长抑素联合复方丹参注射液治疗重症急性胰腺炎的临床疗效优于单用生长抑素,值得进一步推广应用。
Objective To explore the clinical efficacy of combination of somatostatin and compound Danshen injection in treatment of pa-tients with severe acute pancreatitis. Methods A total of 92 patients with acute pancreatitis in this hospital during January to December of 2012 were selected for this study. All these patients were divided into control group and combination treatment group according random number table, each group with 46 cases. Patients in these two groups received combination therapy,patients in control group were additionally treated with soma-tostatin,and patients in combination treatment group were treated with Danshen injection on the basis of treatment in control group. The efficacy, adverse reactions,serum levels of C-reactive protein(CRP)and intercellular adhesion molecule -1(ICAM-1)as indicators were observed in these two groups,and the clinical significance of these drugs were observed. Results After a period of treatment,the clinical status of combined treatment group and control group had been got varying degree of improvement. The effective rate of combination treatment group was 93. 48%, and the effective rate of control group was 88. 10% . The effective rate of combination treatment group was significantly higher than that of control group,and their difference was statistically significant( P 〈0. 05). Adverse reactions had been occurred in 8 cases of combination treatment group,and the rate of adverse reactions was 17. 39%. Adverse reactions had been occurred in 7 cases of control group,and the adverse reaction rate was 15. 22%,and the difference in incidence of adverse reactions between these 2 groups was not statistically significant(χ2 =6. 459,P 〉0. 05). After treatment,the indicators in each group had been changed,and their difference was statistically significant( P 〈0. 05). The serum levels of CRP and ICAM-1 in combination treatment group after treatment were significantly better than those of control group,and their difference was statistically significant( P 〈0. 05). Conclusion The clinical efficacy of combination of somatostatin and compound Danshen injection in treatment of patients with severe acute pancreatitis is much better than that of single medication,hence it is worthy to be recommended for further application.
出处
《临床和实验医学杂志》
2014年第10期811-813,共3页
Journal of Clinical and Experimental Medicine